Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer

Abstract To compare enzalutamide (E) and abiraterone acetate (AA) in terms of efficacy, survival and to characterize prognostic factors affecting survival in metastatic castration-resistant prostate cancer (mCRPC) patients. A total of 250 patients treated with E or AA in 5 centers were included. The...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ayşe Demirci, Cemil Bilir, Burcu Gülbağcı, İlhan Hacıbekiroğlu, İbrahim V. Bayoğlu, İrem Bilgetekin, Sinan Koca, Havva Y. Çınkır, Nadiye Akdeniz, Deniz Gül, Ceyhun Varım, Umut Demirci, Berna Öksüzoğlu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2f1961a10d9b47f5b41b353c34cd4036
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2f1961a10d9b47f5b41b353c34cd4036
record_format	dspace
spelling	oai:doaj.org-article:2f1961a10d9b47f5b41b353c34cd40362021-12-02T18:34:06ZComparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer10.1038/s41598-021-93659-x2045-2322https://doaj.org/article/2f1961a10d9b47f5b41b353c34cd40362021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93659-xhttps://doaj.org/toc/2045-2322Abstract To compare enzalutamide (E) and abiraterone acetate (AA) in terms of efficacy, survival and to characterize prognostic factors affecting survival in metastatic castration-resistant prostate cancer (mCRPC) patients. A total of 250 patients treated with E or AA in 5 centers were included. The number of patients with no prostate specific antigen (PSA) decline was higher in the AA group than that in the E group, and the proportion of patients with a PSA decline of ≥ 50% was higher in the E group (p = 0.020). Radiological progression free survival (rPFS) and overall survival (OS) were significantly longer in the E group when compared to that in the AA group (p < 0.001 and p = 0.027, respectively). In the E group, rPFS was significantly longer than that in the AA group in both pre- and post-docetaxel settings (p = 0.010 and p = 0.003, respectively). OS was similar in the pre-docetaxel setting; but in the post-docetaxel setting, E group had a significantly longer OS than the AA group (p = 0.021). In the multivariate analysis performed in the whole patient group, we found that good prognostic factors for rPFS were E treatment, being ≥ 75 years and a PSA decline of ≥ 50% while there was no factor affecting OS. With longer OS and PFS, E seems to be more suitable for mCRPC patients in the post-docetaxel setting than AA.Ayşe DemirciCemil BilirBurcu Gülbağcıİlhan Hacıbekiroğluİbrahim V. Bayoğluİrem BilgetekinSinan KocaHavva Y. ÇınkırNadiye AkdenizDeniz GülCeyhun VarımUmut DemirciBerna ÖksüzoğluNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ayşe Demirci Cemil Bilir Burcu Gülbağcı İlhan Hacıbekiroğlu İbrahim V. Bayoğlu İrem Bilgetekin Sinan Koca Havva Y. Çınkır Nadiye Akdeniz Deniz Gül Ceyhun Varım Umut Demirci Berna Öksüzoğlu Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
description	Abstract To compare enzalutamide (E) and abiraterone acetate (AA) in terms of efficacy, survival and to characterize prognostic factors affecting survival in metastatic castration-resistant prostate cancer (mCRPC) patients. A total of 250 patients treated with E or AA in 5 centers were included. The number of patients with no prostate specific antigen (PSA) decline was higher in the AA group than that in the E group, and the proportion of patients with a PSA decline of ≥ 50% was higher in the E group (p = 0.020). Radiological progression free survival (rPFS) and overall survival (OS) were significantly longer in the E group when compared to that in the AA group (p < 0.001 and p = 0.027, respectively). In the E group, rPFS was significantly longer than that in the AA group in both pre- and post-docetaxel settings (p = 0.010 and p = 0.003, respectively). OS was similar in the pre-docetaxel setting; but in the post-docetaxel setting, E group had a significantly longer OS than the AA group (p = 0.021). In the multivariate analysis performed in the whole patient group, we found that good prognostic factors for rPFS were E treatment, being ≥ 75 years and a PSA decline of ≥ 50% while there was no factor affecting OS. With longer OS and PFS, E seems to be more suitable for mCRPC patients in the post-docetaxel setting than AA.
format	article
author	Ayşe Demirci Cemil Bilir Burcu Gülbağcı İlhan Hacıbekiroğlu İbrahim V. Bayoğlu İrem Bilgetekin Sinan Koca Havva Y. Çınkır Nadiye Akdeniz Deniz Gül Ceyhun Varım Umut Demirci Berna Öksüzoğlu
author_facet	Ayşe Demirci Cemil Bilir Burcu Gülbağcı İlhan Hacıbekiroğlu İbrahim V. Bayoğlu İrem Bilgetekin Sinan Koca Havva Y. Çınkır Nadiye Akdeniz Deniz Gül Ceyhun Varım Umut Demirci Berna Öksüzoğlu
author_sort	Ayşe Demirci
title	Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
title_short	Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
title_full	Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
title_fullStr	Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
title_full_unstemmed	Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
title_sort	comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2f1961a10d9b47f5b41b353c34cd4036
work_keys_str_mv	AT aysedemirci comparisonofreallifedataofabirateroneacetateandenzalutamideinmetastaticcastrationresistantprostatecancer AT cemilbilir comparisonofreallifedataofabirateroneacetateandenzalutamideinmetastaticcastrationresistantprostatecancer AT burcugulbagcı comparisonofreallifedataofabirateroneacetateandenzalutamideinmetastaticcastrationresistantprostatecancer AT ilhanhacıbekiroglu comparisonofreallifedataofabirateroneacetateandenzalutamideinmetastaticcastrationresistantprostatecancer AT ibrahimvbayoglu comparisonofreallifedataofabirateroneacetateandenzalutamideinmetastaticcastrationresistantprostatecancer AT irembilgetekin comparisonofreallifedataofabirateroneacetateandenzalutamideinmetastaticcastrationresistantprostatecancer AT sinankoca comparisonofreallifedataofabirateroneacetateandenzalutamideinmetastaticcastrationresistantprostatecancer AT havvaycınkır comparisonofreallifedataofabirateroneacetateandenzalutamideinmetastaticcastrationresistantprostatecancer AT nadiyeakdeniz comparisonofreallifedataofabirateroneacetateandenzalutamideinmetastaticcastrationresistantprostatecancer AT denizgul comparisonofreallifedataofabirateroneacetateandenzalutamideinmetastaticcastrationresistantprostatecancer AT ceyhunvarım comparisonofreallifedataofabirateroneacetateandenzalutamideinmetastaticcastrationresistantprostatecancer AT umutdemirci comparisonofreallifedataofabirateroneacetateandenzalutamideinmetastaticcastrationresistantprostatecancer AT bernaoksuzoglu comparisonofreallifedataofabirateroneacetateandenzalutamideinmetastaticcastrationresistantprostatecancer
_version_	1718377910541221888

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer

Ejemplares similares